AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a pioneer in therapeutic acute wound care, is set to present at two key investor conferences in September 2026. The company's senior management, including President and CEO Cary Vance and Chief Financial Officer David O’Toole, will engage with investors at the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.

At these conferences, AVITA plans to showcase its innovative technologies designed to enhance wound healing and accelerate patient recovery times. A standout product in AVITA's portfolio is RECELL®, an FDA-approved solution that utilizes a patient's own skin cells to create Spray-On Skin™, primarily for treating thermal burn and trauma wounds. Furthermore, AVITA holds exclusive rights in the U.S. for marketing and selling Cohealyx®, a collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.

Internationally, RECELL is recognized in various markets, including Europe and Japan, where it is approved for a wide range of skin healing applications. An audio webcast of the fireside chat at the Morgan Stanley event will be available for 90 days post-event on the investor relations section of AVITA Medical’s website.

Investors interested in scheduling one-on-one meetings or securing invitations are encouraged to contact their Lake Street or Morgan Stanley representatives. AVITA Medical’s commitment to providing transformative wound care solutions underlines its strategic importance in the healthcare industry, ultimately aiming to improve clinical outcomes and patient care. For further details, interested parties can visit www.avitamedical.com.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) stands out as a transformative player in the acute wound care sector, particularly with its innovative RECELL® technology. As the company prepares to present at the Lakes Street Capital Markets Best Ideas Growth Conference and the Morgan Stanley Healthcare Conference, there are several key factors investors should consider.

First and foremost, AVITA’s robust pipeline addressing various wound care challenges and its unique approach using Spray-On Skin™ positions it competitively within the healthcare landscape. The FDA-approved RECELL system has demonstrated significant clinical outcomes, which can accelerate market adoption and revenue growth. As the management team articulates their growth strategies at these conferences, investors should pay close attention to insights regarding operational advancements and potential collaborations that could enhance distribution channels.

Moreover, the scheduled investor meetings reflect AVITA’s commitment to engaging with stakeholders, which is critical for building investor confidence. The upcoming presentations will likely provide clarity on the company's financial health, regulatory developments, and market penetration strategies, especially regarding geographic expansions in both the U.S. and international markets.

Investors should also consider the potential for future revenue streams from AVITA’s exclusive rights to Cohealyx® and PermeaDerm®, both designed to support diverse wound care applications. Given the rising prevalence of chronic wounds and increasing healthcare expenditures, AVITA Medical is poised for growth.

In conclusion, as AVITA Medical takes the stage at upcoming conferences, it presents a strong investment opportunity for those looking to capitalize on innovation within the healthcare sector. Keeping an eye on management communications and operational milestones in the coming months could yield fruitful insights and enhance investment decisions.